来源：新浪证券-红岸工作室 1月8日，春立医疗跌2.50%，成交额6894.15万元。两融数据显示，当日春立医疗获融资买入额791.00万 元，融资偿还307.68万元，融资净买入483.32万元。截至1月8日，春立医疗融资融券余额合计3706.22万 元。 截至9月30日，春立医疗股东户数6164.00，较上期增加4.12%；人均流通股46906股，较上期减少 3.95%。2025年1月-9月，春立医疗实现营业收入7.56亿元，同比增长48.75%；归母净利润1.92亿元，同 比增长213.21%。 分红方面，春立医疗A股上市后累计派现4.40亿元。近三年，累计派现3.90亿元。 机构持仓方面，截止2025年9月30日，春立医疗十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股295.85万股，为新进股东。中欧景气精选混合A（020876）位居第五大流通股东，持股 283.26万股，为新进股东。平安低碳经济混合A（009878）位居第八大流通股东，持股210.00万股，相 比上期减少167.00万股。南方医药保健灵活配置混合A（000452）退出十大流通股东之列。 融资方面，春立医疗当日融资买入 ...

中国经济网北京1月8日讯 春立医疗(688236.SH)今日收报25.00元，跌幅2.50%。目前该股处于破发 状态。 春立医疗于2021年12月30日在上交所科创板上市，发行价格为29.81元，发行股份数量3,842.80万 股，保荐机构为华泰联合证券有限责任公司，保荐代表人为张畅、茹涛。 春立医疗上市发行募集资金总额为114,553.87万元，扣除发行费用后募集资金净额为106,712.83万 元，较原拟募集资金净额少93287.17万元。 2021年12月27日，春立医疗发布的招股书显示，公司拟募集资金200,000.00万元，用于骨科植入物 及配套材料综合建设项目、研发中心建设项目、营销网络建设项目、补充流动资金项目。 春立医疗上市发行费用合计7,841.04万元，华泰联合证券有限责任公司获得保荐费用150.00万元、 承销费用6,523.59万元。 (责任编辑：魏京婷) ...

1月7日的资金流向数据方面，主力资金净流入15.96万元，占总成交额0.34%，游资资金净流入186.03万 元，占总成交额4.01%，散户资金净流出201.99万元，占总成交额4.36%。 证券之星消息，截至2026年1月7日收盘，春立医疗(688236)报收于25.64元，上涨0.31%，换手率 0.62%，成交量1.8万手，成交额4634.41万元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 春立医疗2025年三季报显示，前三季度公司主营收入7.56亿元，同比上升48.75%；归母净利润1.92亿 元，同比上升213.21%；扣非净利润1.81亿元，同比上升311.07%；其中2025年第三季度，公司单季度主 营收入2.68亿元，同比上升109.51%；单季度归母净利润7706.19万元，同比上升531.12%；单季度扣非 净利润7451.86万元，同比上升439.4%；负债率15.65%，投资收益321.7万元，财务费用-972.34万元，毛 利率67.27% ...

北京市春立正达医疗器械股份有限公司提交截至2025年12月31日的证券变动月报表，报告显示公司H股 和A股的法定股本、已发行股份及库存股数量均无变动。H股于香港联交所上市，A股于上海证券交易 所上市。截至月底，H股法定股份为95,140,500股，A股法定股份为288,428,000股，总注册资本为人民币 383,568,500元。已发行股份总数未发生变化，库存股数量保持不变。 交易信息汇总 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 资金流向 1月6日主力资金净流入306.99万元；游资资金净流入80.45万元；散户资金净流出387.44万元。 截至2026年1月6日收盘，春立医疗(688236)报收于25.56元，上涨2.61%，换手率1.14%，成交量3.29万 手，成交额8275.97万元。 公司公告汇总 当日关注点 H股市场公告 来自交易信息汇总：1月6日主力资金净流入306.99万元，显示主力对个股短期态度偏积极。 来自公司公告汇总：春立医疗提交截至2025年12月31日证券变动月报表，H股与A股股本结构无变 化。 ...

Core Viewpoint - Spring Medical (688236) has shown significant growth in revenue and net profit, indicating strong performance in the orthopedic medical device sector [2]. Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 756 million yuan, an increase of 48.75% year-on-year [2]. - The net profit attributable to shareholders reached 192 million yuan, up 213.21% year-on-year [2]. - The net profit after deducting non-recurring items was 181 million yuan, reflecting a 311.07% increase year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 268 million yuan, a remarkable increase of 109.51% year-on-year [2]. - The quarterly net profit attributable to shareholders was 77.06 million yuan, up 531.12% year-on-year [2]. - The quarterly net profit after deducting non-recurring items was 74.52 million yuan, an increase of 439.4% year-on-year [2]. - The company's debt ratio stands at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan [2]. - The gross profit margin is reported at 67.27% [2]. Market Activity - As of January 5, 2026, the stock closed at 24.91 yuan, with an increase of 8.87% [1]. - The turnover rate was 1.27%, with a trading volume of 36,600 hands and a transaction amount of 88.41 million yuan [1]. - On January 5, the net outflow of main funds was 3.2551 million yuan, accounting for 3.68% of the total transaction amount [1]. - Retail investors saw a net inflow of 3.7834 million yuan, representing 4.28% of the total transaction amount [1]. Institutional Ratings - In the last 90 days, 8 institutions have given buy ratings for the stock, with an average target price of 31.7 yuan [3].

Core Viewpoint - Spring Medical experienced a slight decline in stock price on December 31, with a trading volume of 24.47 million yuan, indicating a potential shift in investor sentiment and market dynamics [1] Financing Summary - On December 31, Spring Medical had a financing buy-in amount of 1.23 million yuan and a financing repayment of 1.39 million yuan, resulting in a net financing outflow of 0.15 million yuan [1] - The total financing and securities lending balance for Spring Medical reached 38.24 million yuan, with the financing balance accounting for 0.58% of the circulating market value, which is above the 70th percentile level over the past year, indicating a relatively high position [1] - The securities lending aspect showed no shares were repaid or sold on December 31, with a remaining securities lending volume of 200 shares and a balance of 4,576 yuan, also exceeding the 80th percentile level over the past year [1] Company Overview - Beijing Spring Medical Equipment Co., Ltd. was established on February 12, 1998, and went public on December 30, 2021, focusing on the research, production, and sales of implantable orthopedic medical devices [2] - The company's main products include joint prosthetics and spinal implant products, covering major human joints such as hip, knee, shoulder, and elbow, with a comprehensive range of spinal fixation systems [2] - As of September 30, Spring Medical reported a revenue of 756 million yuan for the first nine months of 2025, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, reflecting a significant increase of 213.21% [2] Dividend and Shareholder Information - Since its A-share listing, Spring Medical has distributed a total of 440 million yuan in dividends, with 390 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [2][3] - Notable institutional shareholders include Hong Kong Central Clearing Limited as the fourth largest shareholder with 2.96 million shares, and new entrants like China Europe Economic Growth Mixed A Fund and Ping An Low Carbon Economy Mixed A Fund [3]

Group 1 - The core viewpoint of the news is that Spring Medical has experienced a stock price increase of 2.05% this year, but has seen declines over the past five, twenty, and sixty trading days [2][3] - As of January 5, the stock price is reported at 23.35 yuan per share, with a total market capitalization of 8.956 billion yuan [1] - The company specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] Group 2 - For the period from January to September 2025, Spring Medical achieved operating revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [3] - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years [4] - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [3]

FF301 本月底法定/註冊股本總額： RMB 383,568,500 | 2. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 688236 | 說明 | | 於上海證券交易所上市的A股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 288,428,000 | RMB | | | 1 RMB | | 288,428,000 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 288,428,000 | RMB | | | 1 RMB | | 288,428,000 | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） 茲載列本公司在上海證券交易所網站刊登之《北京市萬商天勤律師事務所關於 北京市春立正達醫療器械股份有限公司差異化分紅事項的專項法律意見》，僅 供參閱。 承董事會命 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國北京，2026年1月5日 截至本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生； 本公司非執行董事為王鑫先生；及本公司獨立非執行董事為徐泓女士、翁杰先生及黃德盛先生。 * 僅供識別 北京市万商天勤律师事务所 关于 （股 份 代 號：1858） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由北京市春立 正達醫療器械股份有限公司（「本公司」）作出。 茲載列本公司在上海證券交易所網站刊登之《北京市春立正達醫療器械股份有 限公司2025年前三季度權益分派實施公告》，僅供參閱。 承董事會命 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國北京，2026年1月5日 截至本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生； 本公司非執行董事為王鑫先生；及本公司獨立非執行董事為徐泓女士、翁杰先生及黃德盛先生。 * 僅供 ...